CELGZ - Celgene Corporation - Contingen

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.7500
-0.0500 (-6.25%)
At close: 2:32PM EDT
Stock chart is not supported by your current browser
Previous Close0.8000
Open0.6899
Bid0.7400 x 2900
Ask1.3500 x 1100
Day's Range0.6898 - 0.8400
52 Week Range0.2000 - 2.6500
Volume30,863
Avg. Volume51,150
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme
    American City Business Journals20 days ago

    Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme

    Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.

  • Soon-Shiong’s NantCell gets $30 million from Celgene
    American City Business Journals4 months ago

    Soon-Shiong’s NantCell gets $30 million from Celgene

    NantCell, a cancer treatment company founded by biotech entrepreneur Dr. Patrick Soon-Shiong, has received an additional $30 million investment from drug maker Celgene Corp.

  • We're sorry this is all we were able to find about this topic.